Histologic Features of Tacrolimus-induced Colonic Injury
Authors:
- 17 June 2021
- journal article
- research article
- Published by Wolters Kluwer Health in American Journal of Surgical Pathology
- Vol. 46 (1) , 118-123
Abstract
Tacrolimus is a common immunosuppressant used in solid organ transplant recipients. Although most patients develop diarrheal symptoms, data regarding patterns of injury in patients taking tacrolimus are limited. We performed this study to characterize tacrolimus-related features of colonic injury. We retrospectively identified colonic samples from 20 patients receiving tacrolimus monotherapy. Records were reviewed for symptoms, endoscopic findings, other medications, and infections. None of the patients had gastrointestinal infections or used other drugs known to cause colonic injury; none had received mycophenolate within 6 months of presentation. Cases were evaluated for the nature and distribution of inflammation and crypt abnormalities, including distortion, destruction, and apoptosis. Eighteen (90%) patients were solid organ transplant recipients. Seventeen (85%) had gastrointestinal symptoms, particularly diarrhea (75%). More than 50% had endoscopic colitis and 15% had ulcers and/or erosions. Most (90%) cases showed regenerative epithelial changes; apoptotic crypt cells were present in 55% and numerous in 10% of cases. Neutrophilic cryptitis was present in 60% of cases; 35% showed crypt destruction. Plasma cell-rich lamina propria inflammation and crypt distortion were observed in 40% and 25% of cases, respectively. There was no correlation between therapy duration and features of chronic injury. We conclude that tacrolimus can cause symptomatic colitis. Histologic abnormalities are often mild, featuring regenerative crypts and scattered apoptotic debris. However, 40% of symptomatic patients have chronic colitis, most likely reflecting drug-induced immune dysregulation. Pathologists should be aware of these associations because colitis often resolves with decreasing drug dosage rather than treatment directed toward inflammatory bowel disease.Keywords
This publication has 24 references indexed in Scilit:
- Two cases of severe de novo colitis in kidney transplant recipients after conversion to prolonged-release tacrolimusTransplant International, 2009
- Spectrum of histologic changes in colonic biopsies in patients treated with mycophenolate mofetilLaboratory Investigation, 2009
- Inflammatory Bowel Disease After Liver Transplantation: Risk Factors for Recurrence and De Novo DiseaseAmerican Journal of Transplantation, 2006
- Tacrolimus‐associated eosinophilic gastroenterocolitis in pediatric liver transplant recipients: Role of potential food allergies in pathogenesisPediatric Transplantation, 2006
- Gastrointestinal complications in renal transplant recipientsTransplant International, 2005
- Severe gastrointestinal complications after 1,515 adult kidney transplantationsTransplant International, 2004
- Diarrhoea following renal transplantationClinical Transplantation, 2002
- Mode of Action of Tacrolimus (FK506): Molecular and Cellular MechanismsTherapeutic Drug Monitoring, 1995
- Randomised trial comparing tacrolimus (FK506) and cyclosporin in prevention of liver allograft rejectionThe Lancet, 1994
- Development and function of T cells in mice rendered interleukin-2 deficient by gene targetingNature, 1991